Literature DB >> 10997625

Thyroid hormones and treatment of obesity.

M Krotkiewski1.   

Abstract

Thyroid hormones have important thermogenic function. Nevertheless, thyroid dysfunctions are often associated with minor changes in body weight and fat mass. On the other hand, both overfeeding and fasting have important effects on iodothyronine metabolism and regulation of deiodinase activity. Although under debate, there are clinical and theoretical reasons to administer low-dose thyroid hormones (T3) in selected obese patients. This short review deals with both pathophysiological and clinical aspects of thyroid hormone used in the therapy of obesity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997625     DOI: 10.1038/sj.ijo.0801294

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  20 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India.

Authors:  Pathik Parikh; Aniruddha Phadke; Prabha Sawant
Journal:  Indian J Gastroenterol       Date:  2015-04-16

Review 3.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Bioenergetic impact of tissue-specific regulation of iodothyronine deiodinases during nutritional imbalance.

Authors:  Renata L Araujo; Denise P Carvalho
Journal:  J Bioenerg Biomembr       Date:  2011-02       Impact factor: 2.945

5.  Thyroid hormone: a resurgent treatment for an emergent concern.

Authors:  Mason T Breitzig; Matthew D Alleyn; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-09-27       Impact factor: 5.464

6.  Prevalence of hypothyroidism in nonalcoholic fatty liver disease.

Authors:  Mangesh R Pagadala; Claudia O Zein; Srinivasan Dasarathy; Lisa M Yerian; Rocio Lopez; Arthur J McCullough
Journal:  Dig Dis Sci       Date:  2011-12-20       Impact factor: 3.199

7.  Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha.

Authors:  Xunshan Ding; Kristin Lichti; Insook Kim; Frank J Gonzalez; Jeff L Staudinger
Journal:  J Biol Chem       Date:  2006-07-05       Impact factor: 5.157

Review 8.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

9.  Drugs in the pipeline for the obesity market.

Authors:  David C Klonoff; Frank Greenway
Journal:  J Diabetes Sci Technol       Date:  2008-09

10.  Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States.

Authors:  Manal M Hassan; Ahmed Kaseb; Donghui Li; Yehuda Z Patt; Jean-Nicolas Vauthey; Melanie B Thomas; Steven A Curley; Margaret R Spitz; Steven I Sherman; Eddie K Abdalla; Marta Davila; Richard D Lozano; Deena M Hassan; Wenyaw Chan; Thomas D Brown; James L Abbruzzese
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.